Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

Cyclin dependent kinase 9 (CDK9), a key regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. Here, we report the characterization of NVP-2 (3), a selective ATP-competitive CDK9 inhibitor; and THAL-SNS-032...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Chem Biol
Main Authors: Olson, Calla M., Jiang, Baishan, Erb, Michael A., Liang, Yanke, Doctor, Zainab M., Zhang, Zinan, Zhang, Tinghu, Kwiatkowski, Nicholas, Boukhali, Myriam, Green, Jennifer L., Haas, Wilhelm, Nomanbhoy, Tyzoon, Fischer, Eric S., Young, Richard A., Bradner, James E., Winter, Georg E., Gray, Nathanael S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5912898/
https://ncbi.nlm.nih.gov/pubmed/29251720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nchembio.2538
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados